Opko Health: Rayaldy's Major Unforeseen Impact

... a Phase III clinical trial to treat Chronic Kidney Disease [CKD], Secondary Hyperparathyroidism [SHPT] and Vitamin D insufficiency. The estimated primary completion date of this trial on file with the FDA is March 2014, which means that this drug ...

http://seekingalpha.com/article/1789962-opko-health-rayaldys-major-unforeseen-impact?source=feed